Background

Oncolytic Viruses (OV) boast a unique mechanism of selectively infecting cancer cells and replicating to destroy tumors. They have long been considered next-generation therapeutics due to their advantage of killing cancer cells without harming normal cells while triggering immune responses. Following the 2015 approval of talimogene laherparepvec (T-VEC), a herpes virus-based therapy, for melanoma, there was intense development momentum; however, subsequent new drug entries remained in a long period of silence.

The main bottlenecks were the early neutralization by the body's immune system and the physical barriers of the Tumor Microenvironment (TME). Upon intravenous administration, the rate of reaching target sites plummeted due to neutralization by antibodies in the blood, and direct injection into lesions failed to diffuse deep into the tumor due to the thick extracellular matrix. The problem of immunosuppressive cells surrounding the tumor extinguishing the spark of the immune response also frequently arose. There was a desperate need for a new weapon to treat patient groups unresponsive or resistant to existing Immune Checkpoint Inhibitors (ICI).

Key Findings

The US Food and Drug Administration (FDA) recently made the final decision to approve a new oncolytic virus agent genetically redesigned to overcome existing limitations. This approval is interpreted as the fruit of platform technology that reduced viral toxicity and enhanced tumor-killing capability through genetic recombination techniques. The research team designed the virus to replicate exclusively in cancer cells by deleting genes essential for normal cell proliferation, thereby targeting only the mutational signaling pathways.

Furthermore, therapeutic efficacy was maximized by inserting genes for Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and immune-activating cytokines. This approach stimulates the immune system with cancer antigens and viral proteins released as infected cancer cells burst, thereby converting so-called 'cold tumors,' where immune cell infiltration is inhibited, into an active state.

Data confirmed in a multi-center Phase 3 clinical trial were sufficient to attract the attention of medical professionals. In a trial of 420 patients with advanced cancer who failed standard therapy, the objective response rate (ORR) was 38.5%, and the complete response (CR) rate was 14.2%. It achieved a result of increasing the median Progression-Free Survival (PFS) by 4.8 months compared to the control group, and in terms of systemic toxicity, the incidence of Grade 3 or higher severe adverse events remained below 10%. It is evaluated that safety verification has been completed, with most cases manifesting only as mild, cold-like symptoms such as fever or chills.

Significance and Outlook

This approval is expected to act as a catalyst to revitalize the overall oncolytic virus market, which had entered a period of stagnation. Beyond monotherapy, the expansion of combination clinical trials with anti-PD-1 and anti-PD-L1 class immune checkpoint inhibitors is expected to gain rapid momentum. This is because when oncolytic viruses break down cancer cells to increase immunogenicity, immune checkpoint inhibitors can create a synergistic effect by sustaining T-cell activity.

Challenges in the commercialization stage, such as manufacturing processes, storage, and distribution, still remain. The process (CMC) for mass-producing live viruses while maintaining batch-to-batch uniformity is more challenging than that for synthetic drugs or conventional antibody therapeutics. Establishing an ultra-low temperature storage system at or below -70°C and complying with in-facility handling safety standards is required. Improvements in formulations capable of intravenous administration and research into next-generation delivery vectors are identified as key factors in determining future market dominance.